1. Home
  2. CTSO vs ALLR Comparison

CTSO vs ALLR Comparison

Compare CTSO & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cytosorbents Corporation

CTSO

Cytosorbents Corporation

SELL

Current Price

$4.52

Market Cap

23.9M

Sector

Health Care

ML Signal

SELL

Logo Allarity Therapeutics Inc.

ALLR

Allarity Therapeutics Inc.

HOLD

Current Price

$0.80

Market Cap

19.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CTSO
ALLR
Founded
1997
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
23.9M
19.3M
IPO Year
2008
2021

Fundamental Metrics

Financial Performance
Metric
CTSO
ALLR
Price
$4.52
$0.80
Analyst Decision
Analyst Count
0
0
Target Price
★ $32.50
N/A
AVG Volume (30 Days)
22.2K
★ 136.5K
Earning Date
11-12-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 65.79
N/A
EPS
N/A
★ N/A
Revenue
★ $22,503,908.00
$320,000.00
Revenue This Year
$2.14
N/A
Revenue Next Year
$16.24
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 48.53
N/A
52 Week Low
$0.30
$0.77
52 Week High
$7.44
$1.84

Technical Indicators

Market Signals
Indicator
CTSO
ALLR
Relative Strength Index (RSI) 46.03 38.05
Support Level $2.88 N/A
Resistance Level $7.20 $1.45
Average True Range (ATR) 0.79 0.09
MACD -0.07 -0.01
Stochastic Oscillator 15.43 3.70

Price Performance

Historical Comparison
CTSO
ALLR

About CTSO Cytosorbents Corporation

CytoSorbents Corp is a leader in blood purification for the treatment of life-threatening conditions in the intensive care unit and cardiac surgery. CytoSorbent's proprietary blood purification technologies are based on biocompatible, high-porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. CytoSorbent's technologies are used in several broad applications. Specifically, two important applications are: the removal of blood thinners during and after cardiothoracic surgery to reduce the risk of severe bleeding, and the removal of inflammatory agents and toxins in common critical illnesses that can cause massive inflammation, organ failure, and patient death. Geographically, in the USA, Germany, and Others.

About ALLR Allarity Therapeutics Inc.

Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States. It is focused on the clinical development of its lead program: Stenoparib, which is being co-developed with a drug specific DRP companion diagnostic.

Share on Social Networks: